The European Commission announced on Friday 22 October that it had established a “portfolio” of ten therapeutic treatments for Covid-19 (see EUROPE 12752/16).
Six of the treatments in the Commission’s sights are already under rolling review or have already been submitted to the European Medicines Agency (EMA) for marketing authorisation.
The other four candidates on the Commission’s list have all received scientific opinions from the EMA and, once sufficient clinical data has been collected, further rolling reviews can begin, the Commission explains.
“These therapeutics will bring treatment to patients across the EU as fast as possible provided that their safety and effectiveness has been confirmed by the European Medicines Agency”, it promises.
The ten treatments include three antiviral monoclonal antibodies, three oral antivirals to be used as soon as possible after infection and four immunomodulators for inpatient treatment.
For more details on the treatments currently under study at the EMA: https://bit.ly/3uOMP9i (Original version in French by Agathe Cherki)